What is the 13F Pro Quality Score for DXCM?

13F Pro ranks DEXCOM INC (DXCM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DXCM's current score at https://13fpro.ai/research/DXCM (free sign-up required for the full ranking).

Where does 13F Pro source DXCM data?

All DEXCOM INC fundamentals and ownership data come directly from SEC EDGAR. DEXCOM INC files with the SEC under CIK 1093557. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DXCM in?

DEXCOM INC (DXCM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives DXCM's revenue?

Per DEXCOM INC's latest 10-Q filed with the SEC on 2026-04-30, the biggest revenue drivers are: Distributor channel ($1,010.3M, +15% YoY); Direct channel ($181.6M, +16% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/DXCM.

What are DXCM's largest expenses?

DEXCOM INC's latest 10-Q reports these as the largest expense items: Cost of sales ($441.6M, -1% YoY); Selling, general and administrative ($349.7M, +13% YoY); Research and development ($145.3M, flat YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is DXCM research updated on 13F Pro?

DXCM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

DEXCOM INC(DXCM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1093557 DXCM stock profile & AI dashboard →

13F Pro Quality Score

77.9/100

Rank #74 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

73.9/100

Profitability

82.8/100

Balance Sheet

90.2/100

Earnings Quality

78.3/100

Free Cash Flow

85.4/100

Institutional Flow

65.5/100

Revenue Scale

76.8/100

Dilution Risk

31.5/100

DXCM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for DEXCOM INC (DXCM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DXCM at 77.9/100 on a 32-signal composite quality model, placing it at rank #74 of 2,879 stocks — the top 5% of the AI-ranked universe. DXCM scores in the top quartile across balance sheet strength (90.2), free cash flow (85.4), profitability (82.8). Shareholder dilution risk is elevated at 31.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), DEXCOM INC reports quarterly revenue of $1.2B, net income of $199.5M, an operating margin of 21.4%. Top institutional holders of DXCM by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. DXCM trades on the Nasdaq exchange and files with the SEC under CIK 1093557. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DXCM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DEXCOM INC directly from SEC EDGAR. DEXCOM INC's 13F Pro composite quality score has ranged between 8 and 79 since 2021, currently 77.9 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about DEXCOM INC

Quirks, history, and lore behind DXCM — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · mid-cap · listed on Nasdaq · headquartered in San Diego, California.
2
The Numbers
Annual revenue around $4 billion, growing fast — yet the company spent years burning cash before turning profitable, because R&D and regulatory approvals are expensive friends.
3
The History
Founded in 1999, it set out to solve one of medicine's most persistent daily headaches: managing blood sugar without constantly stabbing your finger.
4
The Secret
Its devices don't just measure glucose — they do it continuously and in real time, sending readings wirelessly to a phone or smartwatch and alerting users before things go dangerously wrong.
5
The Lore
Its sensors have become so popular they now integrate directly with insulin pumps to create a near-closed-loop artificial pancreas — technology that would have seemed like sci-fi to diabetics a generation ago.
6
The Giveaway
The world's leading maker of continuous glucose monitors, its little wearable sensor on the back of your arm has made the fingerstick lancet feel charmingly obsolete.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving DXCM's Business? Latest 10-Q Breakdown

✓ 24/24 datapoints verified

AI-extracted from DEXCOM INC's 10-Q filed 2026-04-30 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Dexcom Q1 2026 revenue grew 15% YoY to $1.19B with net income up 89% to $199.5M, driven by increased sensor sales volume and improved gross margins from manufacturing efficiencies.

Biggest Revenue Drivers

Total revenue: $1,191.9M+15% YoY

Distributor channel$1,010.3M+15% YoY

Increased sales volume of disposable sensors due to continued growth of worldwide customer base.

Direct channel$181.6M+16% YoY

Direct sales to customers and healthcare professionals.

Largest Expense Items

Cost of sales$441.6M-1% YoY

Decreased primarily due to improved manufacturing efficiencies, higher production volumes, and more favorable manufacturing mix resulting in better absorption of fixed costs.

Selling, general and administrative$349.7M+13% YoY

Increased primarily due to $15.9M higher compensation and related costs and $15.1M incremental advertising and marketing investments.

Research and development$145.3Mflat YoY

Relatively flat due to timing of project spend.

Margins: Gross profit margin expanded to 62.9% in Q1 2026 from 56.9% in Q1 2025, driven by increased sales volume, improved manufacturing efficiencies, higher production volumes, and better absorption of fixed costs. Operating margin increased to 21% from 13% YoY.

Watch Items from the Filing

Multiple securities class action lawsuits and derivative actions pending relating to alleged false/misleading statements about revenue guidance (April 2023-July 2024 period) and device reliability issues (July-September 2025); outcome uncertain and could materially affect business.
Six overlapping putative class action complaints filed by G6/G7 users alleging devices were adulterated, misbranded, or failed to perform as advertised; seeking nationwide classes and substantial damages; outcome uncertain.
Operating cash flow surged 186% YoY to $525.6M in Q1 2026, with strong positive working capital dynamics and cash position of $2.42B as of March 31, 2026.
Added approximately 600,000-700,000 net customers (excluding Stelo) to worldwide base in 2025; pricing headwinds from channel mix and rebate eligibility partially offset volume growth.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$1.2B

Net Income

Q1 2026

$199.5M

Free Cash Flow

Q1 2026

$449.0M

Operating Margin

Q1 2026

21.4%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+15.6% YoY

$4.66BFY 2025

FY20 $1.93BFY21 $2.45BFY24 $4.03BFY25 $4.66B

Net Income

+45.1% YoY

$836.3MFY 2025

FY20 $549.7MFY21 $216.9MFY24 $576.2MFY25 $836.3M

Operating Income

+52.0% YoY

$911.8MFY 2025

FY20 $299.5MFY21 $265.8MFY24 $600.0MFY25 $911.8M

EPS (Diluted)

+47.2% YoY

$2.09FY 2025

FY20 $0.33FY21 $0.13FY24 $1.42FY25 $2.09

Total Assets

-2.2% YoY

$6.34BFY 2025

FY20 $4.29BFY21 $4.93BFY24 $6.48BFY25 $6.34B

Op. Cash Flow

+45.6% YoY

$1.44BFY 2025

FY20 $475.6MFY21 $442.5MFY24 $989.5MFY25 $1.44B

Metric	FY 2025	FY 2024	FY 2021	FY 2020	FY 2019	FY 2017
Revenue	$4.66B +15.6%	$4.03B +64.7%	$2.45B +27.1%	$1.93B +30.5%	$1.48B +105.4%	$718.5M
Net Income	$836.3M +45.1%	$576.2M +165.7%	$216.9M -60.5%	$549.7M +443.7%	$101.1M +301.4%	$-50.2M
Operating Income	$911.8M +52.0%	$600.0M +125.7%	$265.8M -11.3%	$299.5M +110.5%	$142.3M +434.8%	$-42.5M
EPS (Diluted)	$2.09 +47.2%	$1.42 +971.7%	$0.13 -60.2%	$0.33 +383.3%	$0.07 +856.0%	$-0.01
Total Assets	$6.34B -2.2%	$6.48B +31.4%	$4.93B +15.0%	$4.29B +79.1%	$2.40B +164.9%	$904.1M
Operating Cash Flow	$1.44B +45.6%	$989.5M +123.6%	$442.5M -7.0%	$475.6M +51.2%	$314.5M +241.8%	$92.0M

AI Insight: DXCM Financial Trends

DXCM delivered 18.7% YoY revenue growth to $1.19B in Q1 2026 with operating margin expanding to 21.4%, though net income declined sequentially from Q4 2025's $267M peak.

• Revenue grew from $1.004B in Q2 2024 to $1.192B in Q1 2026, a 18.7% increase over nine quarters.

• Operating margin expanded significantly: 15.7% in Q2 2024 to 21.4% in Q1 2026, a 570bp improvement.

• Operating cash flow reached $526M in Q1 2026, second-highest in the dataset, demonstrating strong cash generation.

⚠ Net income declined to $200M in Q1 2026 from $267M in Q4 2025, despite higher operating income, suggesting margin pressures below the operating line.

⚠ Equity volatility persists: swung from $1.979B in Q3 2024 to $2.957B in Q1 2026, indicating capital allocation or goodwill fluctuations.

AI Insight: DXCM Ratio Trends

Operating margin surged to 21.4% TTM from 15.7% two years ago, but Q1 2026 shows seasonal pullback after Q4 2025's exceptional 25.6% peak.

• ROIC improved from 26.0% in Q2 2024 to 34.9% TTM, with Q4 2025 reaching 47.0%—strongest capital efficiency in dataset.

• Net profit margin expanded from 14.3% (Q2 2024) to 19.3% TTM, reflecting operational leverage and cost control.

• ROE climbed from 23.6% (Q2 2024) to 31.5% TTM, demonstrating stronger shareholder returns on invested capital.

⚠ Q1 2026 shows marked quarterly decline across most metrics: OpMargin to 21.4%, ROE to 27.0%, ROIC to 34.5%.

⚠ Q1 2025 was a material dip (OpMargin 12.9%, ROIC 23.6%)—monitor if Q1 seasonality repeats or if trend normalizes.

Get alerted when DXCM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for DEXCOM INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DXCM

BlackRock, Inc.
$2.4B38,964,371 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.6B25,020,961 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.2B19,219,953 sh
STATE STREET CORP
$1.1B17,934,847 sh
BAILLIE GIFFORD & CO
$979.7M15,599,525 sh
ALLIANCEBERNSTEIN L.P.
$857.7M12,923,644 sh
GEODE CAPITAL MANAGEMENT, LLC
$772.9M12,346,638 sh
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME
$612.1M9,746,174 sh
WELLINGTON MANAGEMENT GROUP LLP
$585.7M9,326,240 sh
Amundi
$397.7M6,332,561 sh

Fund	Value	Shares
BlackRock, Inc.	$2.4B	38,964,371
VANGUARD CAPITAL MANAGEMENT LLC	$1.6B	25,020,961
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.2B	19,219,953
STATE STREET CORP	$1.1B	17,934,847
BAILLIE GIFFORD & CO	$979.7M	15,599,525
ALLIANCEBERNSTEIN L.P.	$857.7M	12,923,644
GEODE CAPITAL MANAGEMENT, LLC	$772.9M	12,346,638
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME	$612.1M	9,746,174
WELLINGTON MANAGEMENT GROUP LLP	$585.7M	9,326,240
Amundi	$397.7M	6,332,561

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DXCM on your watchlist

Track score changes the day DEXCOM INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DXCM a good stock to buy?

13F Pro's AI-powered analysis of DEXCOM INC (DXCM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DXCM are available on the DXCM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own DXCM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DXCM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DEXCOM INC's investment landscape.